Guangzhou Huli Technology Co., Ltd. dba Fantasy Face
Has Fantasy Face received an FDA warning letter? Yes. FDA issued a warning letter dated March 31, 2026.
Letter facts
- Letter date
- March 31, 2026 (2026-03-31)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Online / Internet Pharmacy
- Products named
- Googeer GLP-1 Weight Control Oral Solution
- Violation categories
- Unapproved new drugMisbranding
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
Factual Violation Summary
FDA says an eBay store offered Googeer GLP-1 Weight Control Oral Solution, an unapproved new drug not generally recognized as safe and effective, with no FDA-approved application; labeling claims treat weight management and blood sugar balance.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Unapproved new drug
- Misbranding/adulteration under FD&C Act sections 301(d) and 505(a)
More letters about Semaglutide
Recent FDA warning letters concerning Semaglutide:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.